KEGG   PATHWAY: hsa05202Help
Entry
hsa05202                    Pathway                                

Name
Transcriptional misregulation in cancer - Homo sapiens (human)
Description
In tumor cells, genes encoding transcription factors (TFs) are often amplified, deleted, rearranged via chromosomal translocation and inversion, or subjected to point mutations that result in a gain- or loss-of- function. In hematopoietic cancers and solid tumors, the translocations and inversions increase or deregulate transcription of the oncogene. Recurrent chromosome translocations generate novel fusion oncoproteins, which are common in myeloid cancers and soft-tissue sarcomas. The fusion proteins have aberrant transcriptional function compared to their wild-type counterparts. These fusion transcription factors alter expression of target genes, and thereby result in a variety of altered cellular properties that contribute to the tumourigenic process.
Class
Human Diseases; Cancer: overview
BRITE hierarchy
Pathway map
hsa05202  Transcriptional misregulation in cancer
hsa05202

Ortholog table
Network
nt06240  Transcription
nt06260  Colorectal cancer
nt06261  Gastric cancer
nt06262  Pancreatic cancer
nt06263  Hepatocellular carcinoma
nt06264  Renal cell carcinoma
nt06265  Bladder cancer
nt06266  Non-small cell lung cancer
nt06267  Small cell lung cancer
nt06268  Melanoma
nt06269  Basal cell carcinoma
nt06270  Breast cancer
nt06271  Endometrial cancer
nt06272  Prostate cancer
nt06273  Glioma
nt06274  Thyroid cancer
nt06275  Acute myeloid leukemia
nt06276  Chronic myeloid leukemia
nt06319  AHR-cell cycle regulation
nt06360  Cushing syndrome
  Element
N00108  AML1-ETO fusion to transcriptional activtion
N00109  PML-RARA fusion to transcriptional activtion
N00110  PLZF-RARA fusion to transcriptional activtion
N00111  AML1-ETO fusion to CEBPA-mediated transcription
N00112  AML1-ETO fusion to PU.1-mediated transcription
N00113  PML-RARA fusion to transcriptional repression
N00114  PLZF-RARA fusion to transcriptional repression
N00115  Mutation-inactivated TP53 to transcription
N00116  Mutation-inactivated RUNX1 to transcription
N00117  E2A-PBX1 fusion to transcriptional activation
N00118  TEL-AML1 fusion to transcriptional repression
N00119  MLL-AF4 fusion to transcriptional activation
N00120  MLL-ENL fusion to transcriptional activation
N00121  LMO2-rearrangement to transcriptional activation
N00122  LMO2-rearrangement to transcriptional repression
N00123  Amplified REL to transcription
N00124  IGH-MAF fusion to transcriptional activation
N00125  IGH-MMSET fusion to transcriptional activation
N00126  PAX8-PPARG fusion to PPARG-mediated transcription
N00127  PRCC-TFE3 fusion to transcriptional activation
N00128  TMPRSS2-ERG fusion to transcriptional activation
N00129  TMPRSS2-ERG fusion to transcriptional repression
N00130  TMPRSS2-ETV5 fusion to transcriptional activation
N00131  Amplified MYCN to transcriptional activation
N00132  Amplified MYCN to transcriptional repression
N00133  EWSR1-FLI1 fusion to transcriptional activation
N00134  EWSR1-FLI1 fusion to transcriptional repression
N00135  EWSR1-ERG fusion to transcriptional activation
N00136  EWSR1-ATF1 fusion to transcriptional activation
N00137  EWSR1-WT1 fusion to transcriptional activation
N00138  EWSR1-NR4A3
N00139  FUS-DDIT3 fusion to CEBPB-mediated transcription
N00140  FUS-DDIT3 fusion to NFKB-mediated transcription
N00141  PAX3-FOXO1 fusion to transcriptional activation
N00142  SYT-SSX fusion to transcriptional repression
N00143  ASPL-TFE3 fusion to transcriptional activation
N00144  TLX1 rearrangement to transcriptional repression
N00290  Mutation-inactivated MEN1 to transcription
Disease
H00001  B-cell acute lymphoblastic leukemia
H00002  T-cell acute lymphoblastic leukemia
H00003  Acute myeloid leukemia
H00006  Hairy cell leukemia
H00007  Hodgkin lymphoma
H00010  Multiple myeloma
H00011  Lymphoplasmacytic lymphoma
H00021  Renal cell carcinoma
H00024  Prostate cancer
H00032  Thyroid cancer
H00034  Carcinoid
H00035  Ewing sarcoma
H00037  Rhabdomyosarcoma
H00043  Neuroblastoma
H00049  Myxoid liposarcoma
H00050  Synovial sarcoma
H00051  Alveolar soft part sarcoma
H00052  Clear cell sarcoma of soft tissue
H00053  Extraskeletal myxoid chondrosarcoma
H01102  Pituitary adenomas
H01985  Desmoplastic small round cell tumor
Drug
D00094  Tretinoin (JAN/USP/INN)
Organism
Homo sapiens (human) [GN:hsa]
Gene
861  RUNX1; RUNX family transcription factor 1 [KO:K08367]
1436  CSF1R; colony stimulating factor 1 receptor [KO:K05090] [EC:2.7.10.1]
4353  MPO; myeloperoxidase [KO:K10789] [EC:1.11.2.2]
1437  CSF2; colony stimulating factor 2 [KO:K05427]
3562  IL3; interleukin 3 [KO:K04736]
862  RUNX1T1; RUNX1 translocation partner 1 [KO:K10053]
3065  HDAC1; histone deacetylase 1 [KO:K06067] [EC:3.5.1.98]
3066  HDAC2; histone deacetylase 2 [KO:K06067] [EC:3.5.1.98]
25942  SIN3A; SIN3 transcription regulator family member A [KO:K11644]
9611  NCOR1; nuclear receptor corepressor 1 [KO:K04650]
1050  CEBPA; CCAAT enhancer binding protein alpha [KO:K09055]
8864  PER2; period circadian regulator 2 [KO:K02633]
6688  SPI1; Spi-1 proto-oncogene [KO:K09438]
929  CD14; CD14 molecule [KO:K04391]
3684  ITGAM; integrin subunit alpha M [KO:K06461]
2209  FCGR1A; Fc fragment of IgG receptor Ia [KO:K06498]
3728  JUP; junction plakoglobin [KO:K10056]
5371  PML; promyelocytic leukemia [KO:K10054]
5914  RARA; retinoic acid receptor alpha [KO:K08527]
1053  CEBPE; CCAAT enhancer binding protein epsilon [KO:K10051]
597  BCL2A1; BCL2 related protein A1 [KO:K02162]
7704  ZBTB16; zinc finger and BTB domain containing 16 [KO:K10055]
4609  MYC; MYC proto-oncogene, bHLH transcription factor [KO:K04377]
1848  DUSP6; dual specificity phosphatase 6 [KO:K21946] [EC:3.1.3.48 3.1.3.16]
6929  TCF3; transcription factor 3 [KO:K09063]
5087  PBX1; PBX homeobox 1 [KO:K09355]
51384  WNT16; Wnt family member 16 [KO:K01558]
2120  ETV6; ETS variant 6 [KO:K03211]
51513  ETV7; ETS variant 7 [KO:K03211]
1991  ELANE; elastase, neutrophil expressed [KO:K01327] [EC:3.4.21.37]
3002  GZMB; granzyme B [KO:K01353] [EC:3.4.21.79]
4297  KMT2A; lysine methyltransferase 2A [KO:K09186] [EC:2.1.1.43]
4299  AFF1; AF4/FMR2 family member 1 [KO:K15184]
1025  CDK9; cyclin dependent kinase 9 [KO:K02211] [EC:2.7.11.23 2.7.11.22]
904  CCNT1; cyclin T1 [KO:K15188]
905  CCNT2; cyclin T2 [KO:K15188]
4298  MLLT1; MLLT1 super elongation complex subunit [KO:K15187]
4300  MLLT3; MLLT3 super elongation complex subunit [KO:K15187]
84444  DOT1L; DOT1 like histone lysine methyltransferase [KO:K11427] [EC:2.1.1.43]
4005  LMO2; LIM domain only 2 [KO:K15612]
5090  PBX3; PBX homeobox 3 [KO:K15610]
860  RUNX2; RUNX family transcription factor 2 [KO:K09278]
4086  SMAD1; SMAD family member 1 [KO:K04676]
51274  KLF3; Kruppel like factor 3 [KO:K15605]
4208  MEF2C; myocyte enhancer factor 2C [KO:K04454]
3205  HOXA9; homeobox A9 [KO:K21950]
3206  HOXA10; homeobox A10 [KO:K17443]
221037  JMJD1C; jumonji domain containing 1C [KO:K11449] [EC:1.14.11.-]
8091  HMGA2; high mobility group AT-hook 2 [KO:K09283]
7403  KDM6A; lysine demethylase 6A [KO:K11447] [EC:1.14.11.-]
7404  UTY; ubiquitously transcribed tetratricopeptide repeat containing, Y-linked [KO:K11447] [EC:1.14.11.-]
8464  SUPT3H; SPT3 homolog, SAGA and STAGA complex component [KO:K11313]
8842  PROM1; prominin 1 [KO:K06532]
2322  FLT3; fms related tyrosine kinase 3 [KO:K05092] [EC:2.7.10.1]
55589  BMP2K; BMP2 inducible kinase [KO:K08854] [EC:2.7.11.1]
3480  IGF1R; insulin like growth factor 1 receptor [KO:K05087] [EC:2.7.10.1]
1027  CDKN1B; cyclin dependent kinase inhibitor 1B [KO:K06624]
5218  CDK14; cyclin dependent kinase 14 [KO:K08821] [EC:2.7.11.22]
4211  MEIS1; Meis homeobox 1 [KO:K15613]
3207  HOXA11; homeobox A11 [KO:K21951]
6495  SIX1; SIX homeobox 1 [KO:K15614]
51804  SIX4; SIX homeobox 4 [KO:K15615]
2138  EYA1; EYA transcriptional coactivator and phosphatase 1 [KO:K15616] [EC:3.1.3.48]
1031  CDKN2C; cyclin dependent kinase inhibitor 2C [KO:K06622]
3248  HPGD; 15-hydroxyprostaglandin dehydrogenase [KO:K00069] [EC:1.1.1.141]
2892  GRIA3; glutamate ionotropic receptor AMPA type subunit 3 [KO:K05199]
2530  FUT8; fucosyltransferase 8 [KO:K00717] [EC:2.4.1.68]
30012  TLX3; T cell leukemia homeobox 3 [KO:K15607]
3195  TLX1; T cell leukemia homeobox 1 [KO:K09340]
64919  BCL11B; BAF chromatin remodeling complex subunit BCL11B [KO:K22046]
8861  LDB1; LIM domain binding 1 [KO:K15617]
4066  LYL1; LYL1 basic helix-loop-helix family member [KO:K15604]
3087  HHEX; hematopoietically expressed homeobox [KO:K08024]
171558  PTCRA; pre T cell antigen receptor alpha [KO:K06056]
5966  REL; REL proto-oncogene, NF-kB subunit [KO:K09254]
894  CCND2; cyclin D2 [KO:K10151]
7185  TRAF1; TNF receptor associated factor 1 [KO:K03172]
598  BCL2L1; BCL2 like 1 [KO:K04570]
942  CD86; CD86 molecule [KO:K05413]
958  CD40; CD40 molecule [KO:K03160]
604  BCL6; BCL6 transcription repressor [KO:K15618]
102723407  IGH; immunoglobulin heavy variable 4-38-2-like [KO:K06856]
4094  MAF; MAF bZIP transcription factor [KO:K09035]
3695  ITGB7; integrin subunit beta 7 [KO:K06590]
7468  NSD2; nuclear receptor binding SET domain protein 2 [KO:K11424] [EC:2.1.1.43]
440093  H3F3C; H3 histone family member 3C [KO:K11253]
3021  H3F3B; H3 histone family member 3B [KO:K11253]
8351  HIST1H3D; histone cluster 1 H3 family member d [KO:K11253]
8352  HIST1H3C; histone cluster 1 H3 family member c [KO:K11253]
8350  HIST1H3A; histone cluster 1 H3 family member a [KO:K11253]
3020  H3F3A; H3 histone family member 3A [KO:K11253]
8290  HIST3H3; histone cluster 3 H3 [KO:K11253]
126961  HIST2H3C; histone cluster 2 H3 family member c [KO:K11253]
333932  HIST2H3A; histone cluster 2 H3 family member a [KO:K11253]
653604  HIST2H3D; histone cluster 2 H3 family member d [KO:K11253]
8353  HIST1H3E; histone cluster 1 H3 family member e [KO:K11253]
8354  HIST1H3I; histone cluster 1 H3 family member i [KO:K11253]
8355  HIST1H3G; histone cluster 1 H3 family member g [KO:K11253]
8356  HIST1H3J; histone cluster 1 H3 family member j [KO:K11253]
8357  HIST1H3H; histone cluster 1 H3 family member h [KO:K11253]
8358  HIST1H3B; histone cluster 1 H3 family member b [KO:K11253]
8968  HIST1H3F; histone cluster 1 H3 family member f [KO:K11253]
5079  PAX5; paired box 5 [KO:K09383]
7849  PAX8; paired box 8 [KO:K09293]
5468  PPARG; peroxisome proliferator activated receptor gamma [KO:K08530]
6256  RXRA; retinoid X receptor alpha [KO:K08524]
6257  RXRB; retinoid X receptor beta [KO:K08525]
6258  RXRG; retinoid X receptor gamma [KO:K08526]
5546  PRCC; proline rich mitotic checkpoint control factor [KO:K13105]
7030  TFE3; transcription factor binding to IGHM enhancer 3 [KO:K09105]
1026  CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625]
7113  TMPRSS2; transmembrane serine protease 2 [KO:K09633] [EC:3.4.21.-]
2078  ERG; ETS transcription factor ERG [KO:K09435]
5328  PLAU; plasminogen activator, urokinase [KO:K01348] [EC:3.4.21.73]
5327  PLAT; plasminogen activator, tissue type [KO:K01343] [EC:3.4.21.68]
4314  MMP3; matrix metallopeptidase 3 [KO:K01394] [EC:3.4.24.17]
4318  MMP9; matrix metallopeptidase 9 [KO:K01403] [EC:3.4.24.35]
7850  IL1R2; interleukin 1 receptor type 2 [KO:K04387]
6692  SPINT1; serine peptidase inhibitor, Kunitz type 1 [KO:K15619]
2115  ETV1; ETS variant 1 [KO:K09431]
2118  ETV4; ETS variant 4 [KO:K15592]
2119  ETV5; ETS variant 5 [KO:K15593]
85414  SLC45A3; solute carrier family 45 member 3 [KO:K15379]
2005  ELK4; ETS transcription factor ELK4 [KO:K04376]
1655  DDX5; DEAD-box helicase 5 [KO:K12823] [EC:3.6.4.13]
4613  MYCN; MYCN proto-oncogene, bHLH transcription factor [KO:K09109]
4149  MAX; MYC associated factor X [KO:K04453]
4193  MDM2; MDM2 proto-oncogene [KO:K06643] [EC:2.3.2.27]
5747  PTK2; protein tyrosine kinase 2 [KO:K05725] [EC:2.7.10.2]
7157  TP53; tumor protein p53 [KO:K04451]
648  BMI1; BMI1 proto-oncogene, polycomb ring finger [KO:K11459]
100532731  COMMD3-BMI1; COMMD3-BMI1 readthrough [KO:K11459]
6667  SP1; Sp1 transcription factor [KO:K04684]
7709  ZBTB17; zinc finger and BTB domain containing 17 [KO:K10500]
4914  NTRK1; neurotrophic receptor tyrosine kinase 1 [KO:K03176] [EC:2.7.10.1]
4804  NGFR; nerve growth factor receptor [KO:K02583]
4221  MEN1; menin 1 [KO:K14970]
2130  EWSR1; EWS RNA binding protein 1 [KO:K13209]
2313  FLI1; Fli-1 proto-oncogene, ETS transcription factor [KO:K09436]
3479  IGF1; insulin like growth factor 1 [KO:K05459]
3398  ID2; inhibitor of DNA binding 2 [KO:K17693]
7048  TGFBR2; transforming growth factor beta receptor 2 [KO:K04388] [EC:2.7.11.30]
3486  IGFBP3; insulin like growth factor binding protein 3 [KO:K10138]
54738  FEV; FEV transcription factor, ETS family member [KO:K09437]
466  ATF1; activating transcription factor 1 [KO:K09053]
9915  ARNT2; aryl hydrocarbon receptor nuclear translocator 2 [KO:K15589]
472  ATM; ATM serine/threonine kinase [KO:K04728] [EC:2.7.11.1]
4286  MITF; melanocyte inducing transcription factor [KO:K09455]
7490  WT1; WT1 transcription factor [KO:K09234]
5154  PDGFA; platelet derived growth factor subunit A [KO:K04359]
3560  IL2RB; interleukin 2 receptor subunit beta [KO:K05069]
8938  BAIAP3; BAI1 associated protein 3 [KO:K15621]
7102  TSPAN7; tetraspanin 7 [KO:K06571]
4291  MLF1; myeloid leukemia factor 1 [KO:K15622]
8013  NR4A3; nuclear receptor subfamily 4 group A member 3 [KO:K08559]
8148  TAF15; TATA-box binding protein associated factor 15 [KO:K14651]
2521  FUS; FUS RNA binding protein [KO:K13098]
1649  DDIT3; DNA damage inducible transcript 3 [KO:K04452]
1051  CEBPB; CCAAT enhancer binding protein beta [KO:K10048]
3569  IL6; interleukin 6 [KO:K05405]
64332  NFKBIZ; NFKB inhibitor zeta [KO:K14242]
4790  NFKB1; nuclear factor kappa B subunit 1 [KO:K02580]
5970  RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735]
3576  CXCL8; C-X-C motif chemokine ligand 8 [KO:K10030]
2308  FOXO1; forkhead box O1 [KO:K07201]
2321  FLT1; fms related tyrosine kinase 1 [KO:K05096] [EC:2.7.10.1]
6760  SS18; SS18 subunit of BAF chromatin remodeling complex [KO:K15623]
6756  SSX1; SSX family member 1 [KO:K15624]
6757  SSX2; SSX family member 2 [KO:K15625]
727837  SSX2B; SSX family member 2B [KO:K15625]
26471  NUPR1; nuclear protein 1, transcriptional regulator [KO:K15626]
79058  ASPSCR1; ASPSCR1 tether for SLC2A4, UBX domain containing [KO:K15627]
4233  MET; MET proto-oncogene, receptor tyrosine kinase [KO:K05099] [EC:2.7.10.1]
1647  GADD45A; growth arrest and DNA damage inducible alpha [KO:K04402]
4616  GADD45B; growth arrest and DNA damage inducible beta [KO:K04402]
10912  GADD45G; growth arrest and DNA damage inducible gamma [KO:K04402]
581  BAX; BCL2 associated X, apoptosis regulator [KO:K02159]
578  BAK1; BCL2 antagonist/killer 1 [KO:K14021]
1643  DDB2; damage specific DNA binding protein 2 [KO:K10140]
51426  POLK; DNA polymerase kappa [KO:K03511] [EC:2.7.7.7]
1668  DEFA3; defensin alpha 3 [KO:K05230]
330  BIRC3; baculoviral IAP repeat containing 3 [KO:K16060]
5077  PAX3; paired box 3 [KO:K09381]
5081  PAX7; paired box 7 [KO:K09381]
6935  ZEB1; zinc finger E-box binding homeobox 1 [KO:K09299]
8900  CCNA1; cyclin A1 [KO:K06627]
Reference
  Authors
Alcalay M, Orleth A, Sebastiani C, Meani N, Chiaradonna F, Casciari C, Sciurpi MT, Gelmetti V, Riganelli D, Minucci S, Fagioli M, Pelicci PG
  Title
Common themes in the pathogenesis of acute myeloid leukemia.
  Journal
Oncogene 20:5680-94 (2001)
DOI:10.1038/sj.onc.1204642
Reference
  Authors
Scandura JM, Boccuni P, Cammenga J, Nimer SD
  Title
Transcription factor fusions in acute leukemia: variations on a theme.
  Journal
Oncogene 21:3422-44 (2002)
DOI:10.1038/sj.onc.1205315
Reference
  Authors
Roumier C, Fenaux P, Lafage M, Imbert M, Eclache V, Preudhomme C
  Title
New mechanisms of AML1 gene alteration in hematological malignancies.
  Journal
Leukemia 17:9-16 (2003)
DOI:10.1038/sj.leu.2402766
Reference
  Authors
Lutterbach B, Hiebert SW
  Title
Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation.
  Journal
Gene 245:223-35 (2000)
DOI:10.1016/S0378-1119(00)00014-7
Reference
  Authors
Koschmieder S, Halmos B, Levantini E, Tenen DG
  Title
Dysregulation of the C/EBPalpha differentiation pathway in human cancer.
  Journal
J Clin Oncol 27:619-28 (2009)
DOI:10.1200/JCO.2008.17.9812
Reference
  Authors
Johansen LM, Iwama A, Lodie TA, Sasaki K, Felsher DW, Golub TR, Tenen DG
  Title
c-Myc is a critical target for c/EBPalpha in granulopoiesis.
  Journal
Mol Cell Biol 21:3789-806 (2001)
DOI:10.1128/MCB.21.11.3789-3806.2001
Reference
  Authors
Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann WK, Koeffler HP
  Title
Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia.
  Journal
Blood 106:2827-36 (2005)
DOI:10.1182/blood-2005-01-0358
Reference
  Authors
Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W, Behre G
  Title
The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
  Journal
Blood 101:270-7 (2003)
DOI:10.1182/blood-2002-04-1288
Reference
  Authors
Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, Hiddemann W, Ito Y, Tenen DG
  Title
Heterozygous PU.1 mutations are associated with acute myeloid leukemia.
  Journal
Blood 100:998-1007 (2002)
DOI:10.1182/blood.V100.3.998
Reference
  Authors
Jing Y
  Title
The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
  Journal
Leuk Lymphoma 45:639-48 (2004)
DOI:10.1080/10428190310001609933
Reference
  Authors
Muller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Kohler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H
  Title
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.
  Journal
Mol Cell Biol 24:2890-904 (2004)
DOI:10.1128/MCB.24.7.2890-2904.2004
Reference
  Authors
Rice KL, Hormaeche I, Doulatov S, Flatow JM, Grimwade D, Mills KI, Leiva M, Ablain J, Ambardekar C, McConnell MJ, Dick JE, Licht JD
  Title
Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.
  Journal
Blood 114:5499-511 (2009)
DOI:10.1182/blood-2009-03-206524
Reference
  Authors
McWhirter JR, Neuteboom ST, Wancewicz EV, Monia BP, Downing JR, Murre C
  Title
Oncogenic homeodomain transcription factor E2A-Pbx1 activates a novel WNT gene in pre-B acute lymphoblastoid leukemia.
  Journal
Proc Natl Acad Sci U S A 96:11464-9 (1999)
DOI:10.1073/pnas.96.20.11464
Reference
  Authors
Zelent A, Greaves M, Enver T
  Title
Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia.
  Journal
Oncogene 23:4275-83 (2004)
DOI:10.1038/sj.onc.1207672
Reference
  Authors
Sawinska M, Ladon D
  Title
Mechanism, detection and clinical significance of the reciprocal translocation t(12;21)(p12;q22) in the children suffering from acute lymphoblastic leukaemia.
  Journal
Leuk Res 28:35-42 (2004)
DOI:10.1016/S0145-2126(03)00160-7
Reference
  Authors
Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, Croce CM, Nakamura T, Canaani E, Young RA
  Title
Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.
  Journal
Genes Dev 22:3403-8 (2008)
DOI:10.1101/gad.1741408
Reference
  Authors
Xia ZB, Popovic R, Chen J, Theisler C, Stuart T, Santillan DA, Erfurth F, Diaz MO, Zeleznik-Le NJ
  Title
The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression.
  Journal
Proc Natl Acad Sci U S A 102:14028-33 (2005)
DOI:10.1073/pnas.0506464102
Reference
  Authors
Wang QF, Wu G, Mi S, He F, Wu J, Dong J, Luo RT, Mattison R, Kaberlein JJ, Prabhakar S, Ji H, Thirman MJ
  Title
MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
  Journal
Blood 117:6895-905 (2011)
DOI:10.1182/blood-2010-12-324699
Reference
  Authors
Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U, Borkhardt A, Chanda SK, Walker J, Soden R, Hess JL, Slany RK
  Title
Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
  Journal
Mol Cell Biol 24:617-28 (2004)
DOI:10.1128/MCB.24.2.617-628.2004
Reference
  Authors
Riz I, Hawley TS, Johnston H, Hawley RG
  Title
Role of TLX1 in T-cell acute lymphoblastic leukaemia pathogenesis.
  Journal
Br J Haematol 145:140-3 (2009)
DOI:10.1111/j.1365-2141.2008.07556.x
Reference
  Authors
Barth TF, Martin-Subero JI, Joos S, Menz CK, Hasel C, Mechtersheimer G, Parwaresch RM, Lichter P, Siebert R, Mooller P
  Title
Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma.
  Journal
Blood 101:3681-6 (2003)
DOI:10.1182/blood-2002-08-2577
Reference
  Authors
Hinz M, Loser P, Mathas S, Krappmann D, Dorken B, Scheidereit C
  Title
Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.
  Journal
Blood 97:2798-807 (2001)
DOI:10.1182/blood.V97.9.2798
Reference
  Authors
Zuzel M, Cawley JC.
  Title
The biology of hairy cells.
  Journal
Best Pract Res Clin Haematol 16:1-13 (2003)
DOI:10.1016/S1521-6926(02)00082-8
Reference
  Authors
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM
  Title
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.
  Journal
Cancer Cell 5:191-9 (2004)
DOI:10.1016/S1535-6108(04)00019-4
Reference
  Authors
Martinez-Garcia E, Popovic R, Min DJ, Sweet SM, Thomas PM, Zamdborg L, Heffner A, Will C, Lamy L, Staudt LM, Levens DL, Kelleher NL, Licht JD
  Title
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
  Journal
Blood 117:211-20 (2011)
DOI:10.1182/blood-2010-07-298349
Reference
  Authors
Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE, Morgan GJ
  Title
MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.
  Journal
Haematologica 94:78-86 (2009)
DOI:10.3324/haematol.13426
Reference
  Authors
Iida S, Rao PH, Ueda R, Chaganti RS, Dalla-Favera R
  Title
Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32).
  Journal
Leuk Lymphoma 34:25-33 (1999)
DOI:10.3109/10428199909083377
Reference
  Authors
Ohno H, Ueda C, Akasaka T
  Title
The t(9;14)(p13;q32) translocation in B-cell non-Hodgkin's lymphoma.
  Journal
Leuk Lymphoma 36:435-45 (2000)
DOI:10.3109/10428190009148390
Reference
  Authors
Prensner JR, Chinnaiyan AM
  Title
Oncogenic gene fusions in epithelial carcinomas.
  Journal
Curr Opin Genet Dev 19:82-91 (2009)
DOI:10.1016/j.gde.2008.11.008
Reference
  Authors
Brenner JC, Chinnaiyan AM
  Title
Translocations in epithelial cancers.
  Journal
Biochim Biophys Acta 1796:201-15 (2009)
DOI:10.1016/j.bbcan.2009.04.005
Reference
  Authors
Reddi HV, McIver B, Grebe SK, Eberhardt NL
  Title
The paired box-8/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis.
  Journal
Endocrinology 148:932-5 (2007)
DOI:10.1210/en.2006-0926
Reference
  Authors
Medendorp K, van Groningen JJ, Vreede L, Hetterschijt L, Brugmans L, van den Hurk WH, van Kessel AG
  Title
The renal cell carcinoma-associated oncogenic fusion protein PRCCTFE3 provokes p21 WAF1/CIP1-mediated cell cycle delay.
  Journal
Exp Cell Res 315:2399-409 (2009)
DOI:10.1016/j.yexcr.2009.04.022
Reference
  Authors
Kumar-Sinha C, Tomlins SA, Chinnaiyan AM
  Title
Recurrent gene fusions in prostate cancer.
  Journal
Nat Rev Cancer 8:497-511 (2008)
DOI:10.1038/nrc2402
Reference
  Authors
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM
  Title
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
  Journal
Cancer Cell 17:443-54 (2010)
DOI:10.1016/j.ccr.2010.03.018
Reference
  Authors
Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R
  Title
TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.
  Journal
PLoS One 6:e21650 (2011)
DOI:10.1371/journal.pone.0021650
Reference
  Authors
Cai C, Hsieh CL, Omwancha J, Zheng Z, Chen SY, Baert JL, Shemshedini L
  Title
ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.
  Journal
Mol Endocrinol 21:1835-46 (2007)
DOI:10.1210/me.2006-0480
Reference
  Authors
Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM
  Title
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
  Journal
Cancer Res 68:73-80 (2008)
DOI:10.1158/0008-5472.CAN-07-5352
Reference
  Authors
Westermark UK, Wilhelm M, Frenzel A, Henriksson MA
  Title
The MYCN oncogene and differentiation in neuroblastoma.
  Journal
Semin Cancer Biol 21:256-66 (2011)
DOI:10.1016/j.semcancer.2011.08.001
Reference
  Authors
Bell E, Chen L, Liu T, Marshall GM, Lunec J, Tweddle DA
  Title
MYCN oncoprotein targets and their therapeutic potential.
  Journal
Cancer Lett 293:144-57 (2010)
DOI:10.1016/j.canlet.2010.01.015
Reference
  Authors
Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A, Shohet JM
  Title
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
  Journal
Proc Natl Acad Sci U S A 102:731-6 (2005)
DOI:10.1073/pnas.0405495102
Reference
  Authors
Ochiai H, Takenobu H, Nakagawa A, Yamaguchi Y, Kimura M, Ohira M, Okimoto Y, Fujimura Y, Koseki H, Kohno Y, Nakagawara A, Kamijo T
  Title
Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma.
  Journal
Oncogene 29:2681-90 (2010)
DOI:10.1038/onc.2010.22
Reference
  Authors
Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G, Lunec J, Tweddle DA
  Title
p53 is a direct transcriptional target of MYCN in neuroblastoma.
  Journal
Cancer Res 70:1377-88 (2010)
DOI:10.1158/0008-5472.CAN-09-2598
Reference
  Authors
Beierle EA, Trujillo A, Nagaram A, Kurenova EV, Finch R, Ma X, Vella J, Cance WG, Golubovskaya VM
  Title
N-MYC regulates focal adhesion kinase expression in human neuroblastoma.
  Journal
J Biol Chem 282:12503-16 (2007)
DOI:10.1074/jbc.M701450200
Reference
  Authors
Iraci N, Diolaiti D, Papa A, Porro A, Valli E, Gherardi S, Herold S, Eilers M, Bernardoni R, Della Valle G, Perini G
  Title
A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF.
  Journal
Cancer Res 71:404-12 (2011)
DOI:10.1158/0008-5472.CAN-10-2627
Reference
  Authors
Dreijerink KM, Hoppener JW, Timmers HM, Lips CJ
  Title
Mechanisms of disease: multiple endocrine neoplasia type 1-relation to chromatin modifications and transcription regulation.
  Journal
Nat Clin Pract Endocrinol Metab 2:562-70 (2006)
DOI:10.1038/ncpendmet0292
Reference
  Authors
Wu X, Hua X
  Title
Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective.
  Journal
Curr Mol Med 8:805-15 (2008)
DOI:10.2174/156652408786733702
Reference
  Authors
Sakurai A, Murakami A, Sano K, Uchino S, Fukushima Y
  Title
Unusual clinical and pathological presentation of a neuroendocrine tumor in a patient with multiple endocrine neoplasia type 1.
  Journal
Endocr J 56:887-95 (2009)
DOI:10.1507/endocrj.K09E-126
Reference
  Authors
Yang Y, Hua X
  Title
In search of tumor suppressing functions of menin.
  Journal
Mol Cell Endocrinol 265-266:34-41 (2007)
DOI:10.1016/j.mce.2006.12.032
Reference
  Authors
Aman P
  Title
Fusion oncogenes in tumor development.
  Journal
Semin Cancer Biol 15:236-43 (2005)
DOI:10.1016/j.semcancer.2005.01.009
Reference
  Authors
Fukuma M, Okita H, Hata J, Umezawa A
  Title
Upregulation of Id2, an oncogenic helix-loop-helix protein, is mediated by the chimeric EWS/ets protein in Ewing sarcoma.
  Journal
Oncogene 22:1-9 (2003)
DOI:10.1038/sj.onc.1206055
Reference
  Authors
Cironi L, Riggi N, Provero P, Wolf N, Suva ML, Suva D, Kindler V, Stamenkovic I
  Title
IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.
  Journal
PLoS One 3:e2634 (2008)
DOI:10.1371/journal.pone.0002634
Reference
  Authors
Riggi N, Stamenkovic I.
  Title
The Biology of Ewing sarcoma.
  Journal
Cancer Lett 254:1-10 (2007)
DOI:10.1016/j.canlet.2006.12.009
Reference
  Authors
Jedlicka P
  Title
Ewing Sarcoma, an enigmatic malignancy of likely progenitor cell origin, driven by transcription factor oncogenic fusions.
  Journal
Int J Clin Exp Pathol 3:338-47 (2010)
Reference
  Authors
Ordonez JL, Osuna D, Herrero D, de Alava E, Madoz-Gurpide J
  Title
Advances in Ewing's sarcoma research: where are we now and what lies ahead?
  Journal
Cancer Res 69:7140-50 (2009)
DOI:10.1158/0008-5472.CAN-08-4041
Reference
  Authors
Jishage M, Fujino T, Yamazaki Y, Kuroda H, Nakamura T
  Title
Identification of target genes for EWS/ATF-1 chimeric transcription factor.
  Journal
Oncogene 22:41-9 (2003)
DOI:10.1038/sj.onc.1206074
Reference
  Authors
Gerald WL, Haber DA
  Title
The EWS-WT1 gene fusion in desmoplastic small round cell tumor.
  Journal
Semin Cancer Biol 15:197-205 (2005)
DOI:10.1016/j.semcancer.2005.01.005
Reference
  Authors
Filion C, Motoi T, Olshen AB, Lae M, Emnett RJ, Gutmann DH, Perry A, Ladanyi M, Labelle Y
  Title
The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene.
  Journal
J Pathol 217:83-93 (2009)
DOI:10.1002/path.2445
Reference
  Authors
Kim S, Lee HJ, Jun HJ, Kim J
  Title
The hTAF II 68-TEC fusion protein functions as a strong transcriptional activator.
  Journal
Int J Cancer 122:2446-53 (2008)
DOI:10.1002/ijc.23379
Reference
  Authors
Sjogren H, Meis-Kindblom J, Kindblom LG, Aman P, Stenman G
  Title
Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma.
  Journal
Cancer Res 59:5064-7 (1999)
Reference
  Authors
Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman P
  Title
Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
  Journal
Int J Cancer 115:556-60 (2005)
DOI:10.1002/ijc.20893
Reference
  Authors
Goransson M, Andersson MK, Forni C, Stahlberg A, Andersson C, Olofsson A, Mantovani R, Aman P
  Title
The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
  Journal
Oncogene 28:270-8 (2009)
DOI:10.1038/onc.2008.378
Reference
  Authors
Willems SM, Schrage YM, Bruijn IH, Szuhai K, Hogendoorn PC, Bovee JV
  Title
Kinome profiling of myxoid liposarcoma reveals NF-kappaB-pathway kinase activity and casein kinase II inhibition as a potential treatment option.
  Journal
Mol Cancer 9:257 (2010)
DOI:10.1186/1476-4598-9-257
Reference
  Authors
Linardic CM
  Title
PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
  Journal
Cancer Lett 270:10-8 (2008)
DOI:10.1016/j.canlet.2008.03.035
Reference
  Authors
Barber TD, Barber MC, Tomescu O, Barr FG, Ruben S, Friedman TB
  Title
Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma.
  Journal
Genomics 79:278-84 (2002)
DOI:10.1006/geno.2002.6703
Reference
  Authors
Ishida M, Miyamoto M, Naitoh S, Tatsuda D, Hasegawa T, Nemoto T, Yokozeki H, Nishioka K, Matsukage A, Ohki M, Ohta T
  Title
The SYT-SSX fusion protein down-regulates the cell proliferation regulator COM1 in t(x;18) synovial sarcoma.
  Journal
Mol Cell Biol 27:1348-55 (2007)
DOI:10.1128/MCB.00658-06
Reference
  Authors
Jun HJ, Lee J, Lim do H, Park JO, Ahn G, Seo SW, Sung KS, Lim do H, Yoo KH, Choi YL
  Title
Expression of MET in alveolar soft part sarcoma.
  Journal
Med Oncol 27:459-65 (2010)
DOI:10.1007/s12032-009-9234-8
Reference
  Authors
Rivlin N, Brosh R, Oren M, Rotter V
  Title
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.
  Journal
Genes Cancer 2:466-74 (2011)
DOI:10.1177/1947601911408889
Reference
  Authors
Suzuki K, Matsubara H
  Title
Recent advances in p53 research and cancer treatment.
  Journal
J Biomed Biotechnol 2011:978312 (2011)
DOI:10.1155/2011/978312
KO pathway
ko05202   

DBGET integrated database retrieval system